CD33 and hepatic veno-occlusive disease: Similarly, candidate antigens such as CD33 (14, 15) are expressed on healthy myeloid progenitors and raise concern about hepatotoxicity given expression on hepatic Kupffer cells and the occurrence of veno-occlusive disease following treatment with CD33-directed toxin-conjugated antibodies (16).